Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPA for CINV Prevention in BEAM Conditioning for HSCT
NCT03097588Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by OHSU Knight Cancer Institute. Started Apr 2017; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03097588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097588.